Antibody Therapy
Articles tagged with Antibody Therapy
Antibody drugs with strong immune cell binding linked to allergic reactions
Researchers from Chiba University found that antibody therapeutics with stronger Fcγ receptor binding are more likely to be recognized as foreign and associated with higher anaphylaxis risk. High affinities for Fcγ receptors critical determinants of anaphylaxis, study suggests.
Vanderbilt Center for Antibody Therapeutics signs agreement to develop anti-measles antibody treatment
The Vanderbilt Center for Antibody Therapeutics has partnered with Saravir Biopharma to develop human monoclonal antibodies against measles. The antibodies, developed by James Crowe Jr., have shown promising preclinical data in neutralizing the virus and preventing infection in animal models.
Immune response to cancer may cause brain disease
Researchers at Cold Spring Harbor Laboratory found that antibodies produced in response to cancer can attack the brain, causing autoimmune diseases like lupus and multiple sclerosis. The study suggests that these antibodies may be harnessed to develop new treatments for triple-negative breast cancer.
Autoantibodies implicated as drivers of long COVID in new study
A new study suggests that autoantibodies from Long COVID patients can induce persistent pain-like symptoms in mice, providing evidence for a potential causal role of autoantibodies in the condition. The research also highlights distinct biological subgroups and offers hope for targeted antibody-based therapies.
New method reveals hidden stereochemical forms of oxidation in antibody drugs
Researchers developed an integrated NMR and LC–MS approach to distinguish between stereochemical variants of methionine oxidation in antibody drugs. The method resolves subtle structural variations relevant to biologic drug quality, strengthening stability testing and quality assessment.
NMR reveals site-specific structural signatures of therapeutic antibodies without isotope labeling
Researchers developed a novel NMR approach to analyze the structure of therapeutic antibodies without isotope labeling. The technique uses site-specific methyl signals to detect subtle structural variations, including glycosylation patterns and local flexibility. This method has significant implications for ensuring the quality of biol...
HIV antibody opens up new approaches for vaccine development and combination therapies
A newly described HIV antibody targets the V3 glycan site in a different manner than previously known antibodies, remaining effective against virus variants that are resistant to classical V3 antibodies. This breakthrough supports antibody therapy combinations that neutralize the virus more effectively.
Unraveling the mystery of why some cancer treatments stop working
SLAMF6 is a molecule on the surface of immune cells that prevents T cells from effectively attacking tumours. Researchers have developed new monoclonal antibodies that prevent SLAMF6 from interacting with itself, potentially offering an option for patients who no longer respond to PD1 or PDL1 treatments.
Could a treatment redirect the body’s anti-viral immune response to target cancer cells?
Researchers developed a PD-L1-binding antigen presenter that redirects antiviral antibodies to target cancer cells, transforming virus-specific immune memory into precision anti-cancer weapons. This strategy has significant potential for treating hard-to-treat cancers and represents a lower-cost, safer avenue for tumor immunotherapy.
PolyU develops novel antibody targeting fat cell protein, offering new approach to treating metabolism-related liver cancer
Researchers at PolyU have identified a key driver of tumour growth in liver cancer and developed a monoclonal antibody that neutralises this protein. The antibody inhibits the growth and proliferation of FABP4-driven cancer stem cells, enhancing immune cell activity.
Gut microbe–derived butyrate activates immune cells to enhance vaccine efficacy
A study published in Microbiome found that gut microbiome-derived butyrate activates immune cells to enhance vaccine efficacy by promoting T follicular helper (Tfh) cell activity and mucosal antibody production. This discovery highlights the crucial role of gut environment regulation in controlling infections and enhancing vaccine resp...
Yeast cells can be used for rapid testing of cancer immunotherapy
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
Chinese Medical Journal article review: cGAS‑STING pathway emerges as cornerstone for next‑generation immunotherapies
The cGAS-STING pathway plays a crucial role in detecting cellular DNA, triggering type I interferons and cytokines, and modulating immune responses. Its therapeutic potential is being explored in cancer and various diseases, with promising preclinical evidence suggesting its potential as a target for next-generation immunotherapies.
MD Anderson shares latest research breakthroughs
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
Researchers find promising new way to boost the immune response to cancer
Researchers have developed a new way to boost the immune system's response to cancer by using specially engineered antibodies. The antibodies work by clustering multiple immune cell receptors, amplifying the signal that tells T cells to attack cancer cells.
Some antibodies outmaneuver germs from sticking to cells
Researchers discovered that certain antibodies employ unusual tactics to block bacterial adhesion, including creating molecular wedges and conformational traps. These mechanisms could lead to the development of immune therapies targeting glycan-binding cell-attachment proteins produced by bacteria causing urinary tract infections.
Cytomegalovirus breakthrough could lead to new treatments
Researchers developed an engineered antibody that outsmarts cytomegalovirus by avoiding its immune evasion strategies and activating immune cells to attack infected cells. This breakthrough could lead to safer and more effective treatments for vulnerable populations.
Antibody halts triple-negative breast cancer in preclinical models
A new study developed an antibody that blocks several ways TNBC cells survive, grow, and evade the immune system. The antibody suppressed primary tumor growth and reenergized cancer-fighting immune cells, including T-cells and macrophages, in preclinical models.
Calcium-sensitive switch boosts the efficacy of cancer drugs
A new study has developed a calcium-activated delivery system that enables more precise cancer treatment, reducing side effects and improving outcomes. The system uses a 'calcium switch' to target tumor cells, releasing a lethal payload deep within, while sparing healthy tissue.
New antibodies developed that can inhibit inflammation in autoimmune diseases
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
New antivenom shows effectiveness against 17 African snake species
A new broad-spectrum antivenom developed by DTU researchers covers 17 African snake species and provides better protection against tissue damage, with a lower risk of immune reactions. The antivenom has shown impressive results in laboratory studies and could revolutionize the treatment of venomous snakebites in Africa.
Custom-designed receptors boost cancer-fighting T cells
Researchers developed a computational platform to design synthetic protein receptors that can detect tumor signals and boost T cell activity. The new receptors, called T-SenSERs, showed improved tumor control and longer survival in mouse models of lung cancer and multiple myeloma.
New antibody restricts the growth of aggressive and treatment-resistant breast cancers
Scientists at King's College London have developed a potential antibody therapy strategy that restricts the growth of treatment-resistant breast cancers. The 'triple-engineered antibody' harnesses the body's immune defences to attack tumour cells and activates immune cells to kill cancer cells.
New Alliance trial studies targeted therapies for rare adrenal cancers
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
Tagging ‘fake targets’ for antigen-independent immunotherapy
Researchers developed a novel technology to attach 'fake targets' to tumor cells, enabling immune cells to attack regardless of antigen presence. The Univody platform showed promising results in animal models, suppressing tumor growth and triggering broader immune activation.
Researchers take a step towards improved antibody therapy
New research explains why antibody-based drugs become too thick to be injected at high concentrations. Understanding the role of electrical charges, researchers can now predict behavior and develop more stable formulations.
Conversion of IgG antibodies to IgM broadens antibacterial activity
Researchers at UMC Utrecht discovered that converting monoclonal antibodies from IgG to IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant bacterial pathogens. This finding could guide the future design of antibody therapies against bacterial infections.
Antibody discovered that blocks almost all known HIV variants in neutralization assays
A newly identified antibody, 04_A06, has been found to block 98.5% of over 300 different HIV strains in laboratory tests. In humanized mice models, the antibody reduced viral load to undetectable levels, offering a promising approach for HIV prevention and treatment.
CU Anschutz researchers discover how lymphatic endothelials cells help the body remember infections
Researchers at CU Anschutz discovered a genetic program within lymphatic endothelial cells that enables storage and archival of antigens, helping the immune system remember infections. This understanding could lead to improved vaccines and therapies by fine-tuning immune memory.
Insilico Medicine, Mabwell Bioscience, and ChemExpress forging ahead with ADC innovation through strategic collaboration
The partnership enables AI-driven design, antibody development, payload-linker synthesis, and clinical development to accelerate ADC drug discovery and development. The collaboration aims to deliver more effective treatment options for cancer patients worldwide by integrating cutting-edge technology and expertise.
High-volume antibody testing platform could accelerate disease research and treatment development
Researchers developed a high-volume method to rapidly build and test large numbers of antibodies at once, accelerating antibody research and treatment development. The oPool+ display platform has potential applications in influenza vaccination research, infectious disease treatment, and cancer research.
Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps
A daily intranasal corticosteroid treatment with stapokibart resulted in reduced polyp size and improved nasal symptom severity after 24 weeks. Stapokibart, a novel monoclonal antibody, showed efficacy in treating severe uncontrolled chronic rhinosinusitis with nasal polyps.
Resolving the structural basis of therapeutic antibody function in cancer immunotherapy
A team of researchers has visualized the nanoscale architecture of CD20 receptors and their interactions with anti-CD20 antibodies using a novel super-resolution microscopy technique. The study reveals that structural changes in antibody design translate into different receptor patterns and cellular responses, opening up new pathways f...
Immunoglobulin replacement therapy shows no reduction in serious infections for patients with CLL
A study found that immunoglobulin replacement therapy was ineffective in reducing serious infections requiring hospitalization among CLL patients. Despite increasing use of the therapy, infection rates remained high, highlighting a need for better clinical guidelines and evaluation of treatment duration.
‘One and done’: A single shot at birth may shield children from HIV for years, study finds
A new study shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV. The treatment uses an adeno-associated virus to deliver instructions to muscle cells, which produce broadly neutralizing antibodies capable of neutralizing multiple strains of HIV.
Shedding light on why immunotherapy sometimes fails
Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.
Enhancing antibody therapies with polyphenol-conjugated nanocarriers for breast cancer
A novel nanocarrier system utilizing metal-polyphenols enables precise intracellular delivery of therapeutic antibodies into cancer cells. This technology overcomes endosomal entrapment, resulting in suppressed tumor growth and enhanced anti-cancer activity.
New bispecific antibody exploits immune receptor proximity to control autoimmunity
Researchers discovered LAG-3 inhibits T cell activity through spatial proximity to TCR, not ligand binding. This discovery enables precise modulation of autoreactive T cells in autoimmune diseases.
Finding suggests treatment approach for autoimmune diseases
Researchers have developed a novel treatment approach for autoimmune diseases by engineering a protein that holds closely together two signaling complexes on T cells, shutting down those T cells in a limited way. This approach shows promise for treating conditions such as Type-1 diabetes and multiple sclerosis.
ASCO: HER3-targeted antibody-drug conjugate (ADC) shows promise for treatment-resistant solid tumors
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.
Experimental Drug Development Centre granted US FDA fast track designation for antibody-drug conjugate EBC-129 to treat pancreatic ductal adenocarcinoma
The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.
Dual action immunotherapy in CAR-T cells improves control of B-ALL progression
Researchers developed a dual action immunotherapy using CAR-T cells targeting CD19 and CD22 proteins in B-ALL cancer cells, increasing the efficacy of treatment and reducing relapse rates.
Delivering a one-two punch to superbugs to fight infections
Researchers at the University of Pennsylvania have created mirror-image molecules that both directly attack bacterial membranes and stimulate the immune system. The dual-action peptides have shown promise in treating infections by reducing bacterial counts and speeding healing, while also promoting sustained immune response.
A new druggable cancer target: RNA-binding proteins on the cell surface
Researchers have discovered a new druggable cancer target, NPM1, which is expressed on the surface of malignant AML cells. Monoclonal antibodies targeting NPM1 showed robust anti-tumor activity in multiple in vivo models of AML, with no apparent toxicity to non-cancerous blood cells and stem cells.
Most COVID-19 treatments found to be free of serious side effects in analysis of U.S. studies
The study analyzed 54 U.S. studies and found no significant association with serious adverse events for oral antivirals like Paxlovid or monoclonal antibodies. Actemra was associated with infection and low white blood cell counts, while transfusions of convalescent plasma were linked to internal bleeding and blood clots.
Study shows how new antibody therapy works against ovarian cancer
Researchers have shed light on how a new type of antibody treatment works against ovarian cancer by reactivating patients' immune cells. The study shows that MOv18 IgE reverses the suppression of immune cells and induces them to kill cancer cells, providing new insights into this therapy.
Advanced imaging reveals mechanisms that cause autoimmune disease
A study using cryo-electron microscopy revealed that autoantibodies in myasthenia gravis disrupt acetylcholine receptor function by blocking or activating the immune system's complement pathway. This knowledge helps explain treatment variability and offers a foundation for personalized therapies targeting specific antibody interactions.
KAIST Develops Retinal Therapy to Restore Lost Vision
Researchers at KAIST have successfully developed a treatment method that restores vision by inducing retinal regeneration and vision recovery in disease-model mice. The approach involves blocking the PROX1 protein, which suppresses retinal regeneration, using an antibody developed by Celliaz Inc.
Blood cancer patients taking Bruton Tyrosine Kinase inhibitors should continue treatment at the time of COVID-19 vaccination, study shows
A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.
Lupus-related antibody shows promise in enhancing cancer treatment efficacy
Researchers at Yale University discovered a lupus-related antibody that can trigger immune responses against certain tumors. The antibody has significantly prolonged survival in brain tumor models without radiation or chemotherapy. This breakthrough could lead to improved strategies for non-viral gene delivery and immunotherapy treatment.
Engineering antibodies with a novel fusion protein
Scientists at Sanford Burnham Prebys developed a new method of generating antibodies by fusing two immune system proteins, enabling the creation of stable monoclonal antibodies. This breakthrough has potential applications in diagnosing and monitoring diseases such as lupus and cancers.
Decoys for misguided antibodies restore antiviral immune defense
Scientists from the University of Zurich created decoy molecules that bind to autoantibodies, preventing them from inhibiting type I interferons. This restoration restores antiviral effect on viruses like influenza, offering hope for treatment and reducing viral disease susceptibility.
Pediatric investigation study releases updated guidelines for pediatric mycoplasma pneumoniae infection
The Chinese Medical Association has released updated guidelines for pediatric mycoplasma pneumoniae infection, emphasizing a multi-faceted diagnostic approach and evidence-based treatment strategies. The guidelines highlight the importance of accurate diagnosis and responsible antibiotic use to combat rising resistance.
The relationship between gut microbiota, immunoglobulin A, and vaccine efficacy
A study has established the importance of immunoglobulin A in generating a response to pneumonia vaccines. The research found that poor regulation of gut microbiota can lead to an inadequate immune response, leaving individuals vulnerable to respiratory infections.
New antibody reduces tumor growth in treatment-resistant breast and ovarian cancers
A new type of antibody that stimulates the immune system to target cancer cells has shown promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. The study found that the antibody, IgE, uniquely stimulated otherwise inactive immune cells to directly target HER2-expressing cancer cells.
Prevalence of neutralizing antibodies to AAV2 and AAV9 in individuals with Niemann-Pick disease
A study published in Human Gene Therapy found that over half of individuals with Niemann-Pick disease type C1 lacked neutralizing antibodies against AAV2 and AAV9. This absence of antibodies may impact the effectiveness of gene therapy treatments for this rare disorder.
VUMC to develop AI technology for therapeutic antibody discovery
Researchers at Vanderbilt University Medical Center aim to use artificial intelligence technologies to generate antibody therapies against specific antigen targets. The project, funded by $30 million from ARPA-H, will create a massive antibody-antigen atlas and develop AI-based algorithms to engineer antigen-specific antibodies.
New antibodies show potential to defeat all SARS-CoV-2 variants
Researchers at Stanford University have discovered a method to use two antibodies to effectively combat the constantly evolving virus, which could lead to longer-lasting treatments for COVID-19. The antibodies were shown to be effective against all SARS-CoV-2 variants in laboratory testing.
Research identifies key antibodies for development of broadly protective norovirus vaccine
Researchers have identified powerful antibodies capable of neutralizing a wide range of norovirus strains, paving the way for designing a broadly effective norovirus vaccine. The discovery brings us closer to a vaccine that could provide lasting protection and prevent devastating effects of norovirus outbreaks.